Female Health Company (The) (VERU) Director Purchases $51,717.50 in Stock
Female Health Company (The) (NASDAQ:VERU) Director Harry Fisch acquired 34,250 shares of the stock in a transaction dated Wednesday, September 13th. The stock was bought at an average cost of $1.51 per share, with a total value of $51,717.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Female Health Company (NASDAQ VERU) traded up 7.33% during midday trading on Thursday, hitting $1.61. The stock had a trading volume of 96,755 shares. Female Health Company has a 52-week low of $0.72 and a 52-week high of $1.68. The firm’s 50 day moving average price is $1.38 and its 200 day moving average price is $1.15.
Female Health Company (The) (NASDAQ:VERU) last issued its earnings results on Tuesday, August 8th. The company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.05. The business had revenue of $4.31 million for the quarter, compared to analysts’ expectations of $2.20 million. Female Health Company (The) had a negative return on equity of 16.78% and a negative net margin of 42.02%. Equities research analysts expect that Female Health Company will post ($0.17) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Female Health Company (The) (VERU) Director Purchases $51,717.50 in Stock” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/14/female-health-company-the-veru-director-purchases-51717-50-in-stock.html.
Several equities research analysts have recently weighed in on VERU shares. HC Wainwright set a $5.00 price target on Female Health Company (The) and gave the stock a “buy” rating in a report on Wednesday, July 26th. Rodman & Renshaw started coverage on Female Health Company (The) in a report on Wednesday, July 26th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, ValuEngine upgraded Female Health Company (The) from a “sell” rating to a “hold” rating in a report on Thursday, August 31st.
About Female Health Company (The)
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.